BOK Financial’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.67M | Buy |
3,164
+195
| +7% | +$109K | 0.02% | 354 |
|
|
2026
Q1 | $1.67M | Buy |
2,969
+599
| +25% | +$384K | 0.03% | 347 |
|
|
2025
Q4 | $1.6M | Sell |
2,370
-334
| -12% | -$227K | 0.02% | 355 |
|
|
2025
Q3 | $1.73M | Sell |
2,704
-103
| -4% | -$62.5K | 0.03% | 369 |
|
|
2025
Q2 | $1.51M | Buy |
2,807
+22
| +0.8% | +$10.5K | 0.02% | 390 |
|
|
2025
Q1 | $1.17M | Sell |
2,785
-461
| -14% | -$200K | 0.02% | 416 |
|
|
2024
Q4 | $1.36M | Sell |
3,246
-29
| -0.9% | -$12.7K | 0.02% | 401 |
|
|
2024
Q3 | $1.58M | Sell |
3,275
-150
| -4% | -$72.9K | 0.03% | 382 |
|
|
2024
Q2 | $1.67M | Sell |
3,425
-134
| -4% | -$67.3K | 0.03% | 390 |
|
|
2024
Q1 | $1.89M | Buy |
3,559
+53
| +2% | +$29K | 0.03% | 376 |
|
|
2023
Q4 | $1.95M | Sell |
3,506
-70
| -2% | -$32.9K | 0.04% | 354 |
|
|
2023
Q3 | $1.43M | Sell |
3,576
-2,042
| -36% | -$1.02M | 0.03% | 381 |
|
|
2023
Q2 | $2.82M | Buy |
5,618
+10
| +0.2% | +$4.79K | 0.06% | 284 |
|
|
2023
Q1 | $2.8M | Sell |
5,608
-2,589
| -32% | -$1.24M | 0.06% | 280 |
|
|
2022
Q4 | $3.34M | Sell |
8,197
-1,510
| -16% | -$586K | 0.06% | 279 |
|
|
2022
Q3 | $3.16M | Sell |
9,707
-1,458
| -13% | -$536K | 0.06% | 272 |
|
|
2022
Q2 | $3.92M | Buy |
11,165
+94
| +0.8% | +$38.3K | 0.08% | 239 |
|
|
2022
Q1 | $6.06M | Sell |
11,071
-2,296
| -17% | -$1.21M | 0.1% | 199 |
|
|
2021
Q4 | $8.8M | Buy |
13,367
+978
| +8% | +$614K | 0.14% | 162 |
|
|
2021
Q3 | $7.7M | Buy |
+12,389
| New | +$8.32M | 0.13% | 168 |
|
|
2021
Q1 | $6.18M | Sell |
12,629
-2,248
| -15% | -$1.13M | 0.11% | 184 |
|
|
2020
Q4 | $7.44M | Sell |
14,877
-242
| -2% | -$108K | 0.14% | 149 |
|
|
2020
Q3 | $5.94M | Buy |
15,119
+3,978
| +36% | +$1.47M | 0.13% | 161 |
|
|
2020
Q2 | $3.68M | Sell |
11,141
-185
| -2% | -$53.6K | 0.09% | 221 |
|
|
2020
Q1 | $2.74M | Buy |
11,326
+5,619
| +98% | +$1.47M | 0.08% | 243 |
|
|
2019
Q4 | $1.49M | Sell |
5,707
-4,903
| -46% | -$1.29M | 0.03% | 419 |
|
|
2019
Q3 | $2.89M | Buy |
10,610
+8,594
| +426% | +$2.39M | 0.07% | 279 |
|
|
2019
Q2 | $556K | Buy |
2,016
+31
| +2% | +$7.64K | 0.01% | 644 |
|
|
2019
Q1 | $444K | Buy |
1,985
+100
| +5% | +$20.6K | 0.01% | 706 |
|
|
2018
Q4 | $351K | Sell |
1,885
-214
| -10% | -$43.9K | 0.01% | 697 |
|
|
2018
Q3 | $524K | Sell |
2,099
-57
| -3% | -$13.8K | 0.01% | 671 |
|
|
2018
Q2 | $470K | Buy |
2,156
+50
| +2% | +$10.3K | 0.01% | 678 |
|
|
2018
Q1 | $403K | Sell |
2,106
-2,531
| -55% | -$467K | 0.01% | 696 |
|
|
2017
Q4 | $725K | Sell |
4,637
-182
| -4% | -$28.6K | 0.02% | 566 |
|
|
2017
Q3 | $749K | Buy |
4,819
+781
| +19% | +$123K | 0.02% | 553 |
|
|
2017
Q2 | $651K | Sell |
4,038
-297
| -7% | -$48.2K | 0.02% | 566 |
|
|
2017
Q1 | $670K | Sell |
4,335
-49
| -1% | -$6.75K | 0.02% | 579 |
|
|
2016
Q4 | $514K | Buy |
+4,384
| New | +$500K | 0.02% | 625 |
|
Other funds holding IDXX
BOK Financial's IDXX Position: Q2 2026 in Review
BOK Financial increased its Idexx Laboratories (IDXX) stake by 6.6% in Q2 2026, buying an estimated $109K and bringing the position to 3,164 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #354.
BOK Financial first reported a position in IDXX in Q4 2016 and has held it in 38 quarters since. The position peaked at $8.8M in Q4 2021. 1,293 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- BOK Financial held 3,164 shares of Idexx Laboratories worth $1.67M as of Q2 2026.
- BOK Financial bought 195 Idexx Laboratories shares in Q2 2026, an estimated $109K.
- Idexx Laboratories made up 0.02% of BOK Financial's portfolio in Q2 2026, its #354 holding.
- BOK Financial first reported a position in Idexx Laboratories in Q4 2016 and has held it in 38 quarters since.
- BOK Financial's Idexx Laboratories position peaked at $8.8M in Q4 2021.
- 1,293 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.